Effect of Olanzapine on Sleep Electroencephalogram (EEG) in Schizophrenia Patients
|ClinicalTrials.gov Identifier: NCT01149577|
Recruitment Status : Completed
First Posted : June 23, 2010
Last Update Posted : June 23, 2010
|Condition or disease||Intervention/treatment||Phase|
|Schizophrenia Sleep||Drug: Olanzapine||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||25 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Study Start Date :||August 2007|
|Actual Primary Completion Date :||December 2007|
|Actual Study Completion Date :||April 2009|
Experimental: Schizophrenia patients
The study population of 25 schizophrenia patients constituted the active arm of the study.
06 weeks treatment with Olanzapine in a flexible dosage schedule.
- Sleep EEG [ Time Frame: 06 weeks ]Changes in Sleep EEG parameters like Total sleep time, total sleep period, sleep efficiency, sleep latency, stage shifts, stage 1 shifts, stage 1 parameters, stage 2 parameters, stage 3 parameters, stage 4 parameters, rapid eye movement (REM) parameters.
- Psychopathology [ Time Frame: 06 weeks ]Changes in psychopathological scores as measured by Brief Psychiatric Rating Scale (BPRS) and Positive and Negative Syndrome Scale (PANSS).
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01149577
|Central Institute of Psychiatry|
|Ranchi, Jharkhand, India, 834006|
|Principal Investigator:||Mohammad Zia Ul Haq Katshu, DPM||Central Institute of Psychiatry|